Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | PRKACG | P22612 | 1/20 | 0.58 |
| ▸ | PRKACB | P22694 | 1/20 | 0.58 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.56 |
| ▸ | GRM5 | P41594 | 5/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336933 | 1.00 | PRKACA (0.58) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL14395236 | 0.88 | PARP10 (0.56) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL31098601 | 0.85 | SMYD3 (0.53) | PRKACAPRKACGPRKACBGRM5PARP1 | |
| SCHEMBL4611577 | 0.85 | SMYD3 (0.53) | PRKACAPRKACGPRKACBGRM5PARP1 | |
| SCHEMBL22401619 | 0.85 | MAPK1 (0.57) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL1727165 | 0.83 | PARP11 (0.72) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL1417726 | 0.81 | PARP11 (0.58) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL30337030 | 0.81 | PARP11 (0.58) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL30421037 | 0.80 | PARP10 (0.57) | PRKACAPRKACGPRKACBPARP11PARP10 | |
| SCHEMBL30445913 | 0.80 | MAPT (0.54) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| CN-119173512-A | Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4430041-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20190270733-A1 | Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof | GOLUB CAPITAL LLC, AS COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
| EP-2683710-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | PRKACA 271/4885PRKACG 449/4885PRKACB 324/4885 |
| US-20190270733-A1 | Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof | HDAC5, HDAC1, HDAC2 | PRKACA 3489/4885PRKACG 3121/4885PRKACB 3214/4885 |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | PRKACA 2382/4885PRKACG 2318/4885PRKACB 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.